Z
Zhongya Sun
Researcher at Harbin Institute of Technology
Publications - 6
Citations - 58
Zhongya Sun is an academic researcher from Harbin Institute of Technology. The author has contributed to research in topics: Bromodomain & BRD4. The author has an hindex of 4, co-authored 6 publications receiving 33 citations. Previous affiliations of Zhongya Sun include Nanchang University.
Papers
More filters
Journal ArticleDOI
Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion
Zhongya Sun,Hao Zhang,Yuanyuan Zhang,Liping Liao,Wen Zhou,Fengcai Zhang,Fengcai Zhang,Fulin Lian,Jing Huang,Pan Xu,Rukang Zhang,Wenchao Lu,Mingrui Zhu,Hongru Tao,Feng Yang,Feng Yang,Hong Ding,Shijie Chen,Liyan Yue,Bing Zhou,Naixia Zhang,Minjia Tan,Hualiang Jiang,Kaixian Chen,Kaixian Chen,Bo Liu,C.Q. Liu,Yongjun Dang,Cheng Luo +28 more
TL;DR: A novel allosteric regulatory site within the Rho family is revealed, which can be exploited for anti‐metastasis drug development, and also provides a novel strategy for inhibitor discovery toward “undruggable” protein targets.
Journal ArticleDOI
Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
Zhongya Sun,Hao Zhang,Zhifeng Chen,Yiqian Xie,Hao Jiang,Limin Chen,Hong Ding,Yuanyuan Zhang,Hualiang Jiang,Mingyue Zheng,Cheng Luo +10 more
TL;DR: Results indicated that this novel BRD 4-BD1 inhibitor DCBD-005 is promising to be developed into a drug candidate in the treatment of BRD4-related diseases.
Journal ArticleDOI
Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
Fengcai Zhang,Zhongya Sun,Liping Liao,Yu Zuo,Yu Zuo,Dan Zhang,Dan Zhang,Jun Wang,Jun Wang,Yantao Chen,Senhao Xiao,Hao Jiang,Tian Lu,Tian Lu,Pan Xu,Liyan Yue,Daohai Du,Daohai Du,Hao Zhang,C.Q. Liu,Cheng Luo,Cheng Luo,Cheng Luo +22 more
TL;DR: A TR-FRET-based high-throughput screening platform for the CBP BrD and acetylated H4 peptide is established and a novel chemical scaffold for further medicinal chemistry optimization and a potential chemical probe for CBP-related biological function research is found.
Journal ArticleDOI
A Sphingosine-1-Phosphate Modulator Ameliorates Polycystic Kidney Disease in Han:SPRD Rats.
Li Xin,Ming Wu,Limin Chen,Limin Chen,Junyan Lu,Li Guo,Lili Fu,Na Qi,Ye Lin,Zhongya Sun,Wang Xueqi,Hao Zhang,Jingqiu Liu,Hualiang Jiang,Lin Li,Changlin Mei,Cheng Luo +16 more
TL;DR: FTY720 significantly reduced cyst growth and delayed disease progression by reducing the accumulation of S1P, thereby inhibiting inflammatory responses, and suggests that FTY720 may serve as a therapeutic agent for clinical autosomal dominant PKD treatment.
Journal ArticleDOI
Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain.
Yu Chen,Xiaoyang Bi,Fengcai Zhang,Zhongya Sun,Pan Xu,Hao Jiang,Wenchao Lu,Tian Lu,Hong Ding,Naixia Zhang,Hualiang Jiang,Kaixian Chen,Bing Zhou,Cheng Luo +13 more
TL;DR: DC-CPin711 showed potent in vitro inhibitory activities to CBP bromodomain with a decent selectivity towards BRD4 bromODomains and good cellular activity to leukemia cells, which could further be applied to related biological and translational studies as well as serve as a lead compound for future development of potent and selective CBPs.